Provider-guided programs
How do you evaluate a peptide provider?
Verify four things before trusting any peptide provider: the clinician’s license against the state board, the pharmacy’s license and accreditation, fully separated pricing for membership, clinical care, and medication, and marketing that never guarantees prescriptions or outcomes. Failure on any one is disqualifying.
The checklist
- Named providers with verifiable state licenses
- Named pharmacy with verifiable licensure and, for compounding, accreditation
- Medication priced separately from membership or consultation
- Regulatory status of every compound stated plainly
- Risks and contraindications published before promotional content
- No prescription or outcome guarantees anywhere
- A public corrections and adverse-event process
Marketing patterns that predict trouble
- Dose menus published before any medical history is taken
- "FDA-compliant" claims without saying what is compliant
- Compounded products described as FDA-approved
- Discounts or points tied to choosing medication
- Anonymous "medical teams"
Why we publish this against our own interest
A checklist this strict also constrains us — that is the point. Programs confident in their standards should welcome verification.
References
- US Food and Drug Administration (2024). FDA's concerns with unapproved GLP-1 drugs used for weight loss. FDA Drug Alerts and Statements. SourceAgency notice
- US Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA Human Drug Compounding. SourceAgency notice
- US Food and Drug Administration (2023). Human drug compounding: compounded drugs are not FDA-approved. FDA. SourceAgency guidance
Found an error? Report a correction.